COVID-19 Infection | Norton Healthcare

Indication: COVID-19 Infection

A Phase 2, Open label Randomized Study of the Efficacy and Safety of Acalabrutinib (a BTK inhibitor) with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19

Hospitalized patients

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Acerta Pharma BV

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.